Family history of disease and risk of glioma occurrence: Results of the  case-control study

Ana  Azanjac Arsić; Gordana Tončev; Svetlana Miletić Drakulić; Katarina Vesić; Dejan Aleksić; Gorica Marić; Tatjana Pekmezović

doi:10.2298/VSP191127001A

Ana Azanjac Arsić University of Kragujevac, Faculty of Medical Sciences, Department of Neurology
Gordana Tončev University of Kragujevac, Faculty of Medical Sciences, Department of Neurology
Svetlana Miletić Drakulić University of Kragujevac, Faculty of Medical Sciences, Department of Neurology
Katarina Vesić University of Kragujevac, Faculty of Medical Sciences, Department of Neurology
Dejan Aleksić University of Kragujevac, Faculty of Medical Sciences, Department of Neurology
Gorica Marić University of Belgrade, Faculty of Medicine, Institute of Epidemiology
Tatjana Pekmezović University of Belgrade, Faculty of Medicine, Institute of Epidemiology

DOI: https://doi.org/10.2298/VSP191127001A

Keywords: glioma, family history of disease;, medical history taking;, epidemiology;, neoplasms

Abstract

Background/Aim. Malignant gliomas represent a heterogenaus group of tumors. They occur in all age groups, predominatly in males in older age. The purpose of this case-control study was to examine the association between risk for developing glioma and family history of diseases. Methods. The case-control study included 100 pathologically confirmed cases of glioma at the Clinical Centre Kragujevac, Serbia, between 2015 and 2016, and 200 age- and sex-matched controls without glioma and other malignant diseases in personal and family history at the same institution. After signing the informed consent all the patients filled out an epidemiological questionnaire. Multivariate logistic regression analysies was used in statistical data processing. Results. Malignant diseases in family history were more common in the study group than in the control group [odds ratio (OR) = 1.821, 95% confidence interval (CI) 1.004–3.305; p = 0.049]. The most common malignant tumor in the study group were cancer of the uterus (7%) and colon cancer (6%), while in the control group the most common cancer were lung cancer (6%) and cancer of the uterus (7%). Diabetes mellitus in family history was more common among control individuals than among glioma patients (OR = 0.520, 95% CI = 0.271–0.995; p = 0.048). Also, our results showed that cardiovascular diseases in family history were more common in the control group than among patients of the study group (OR = 0.557, 95% CI = 0.325–0.953; p = 0.033). Conclusion. In this case-control study, we observed a statistically significant relation between family history of malignant diseases and glioma. Also, we found statistically significant inverse relation between family history of cardiovascular diseases and diabetes and glioma.

Author Biography

Ana Azanjac Arsić, University of Kragujevac, Faculty of Medical Sciences, Department of Neurology

doktor medicine

saradnik u nastavi na Katedri za neurologiju

References

Cbutrus. Statistical Report. Primary brain and central nervous system tumors diagnosed in the United States in 2004-2008. Hinsdale, IL: Central Brain Tumor Registry of the United States; 2012.

Louis DN. Molecular pathology of malignant glioma. Annu Rev Pathol 2006; 1: 97-117.

Watkins S, Sontheimer H. Unique biology of gliomas: challenges and opportunities. Trends Neurosci 2012; 35(9): 546-556.

Wrensch M, Minn Y, Chew T, Bondy M, Berger MS. Epidemiology of primary brain tumors: current concepts and review of the literature. NeuroOncol 2002; 4(4): 278-99.

Inskip PD, Linet MS, Heineman EF. Etiology of brain tumors in adults. Epidemiol Rev 1995; 17(2): 382-414

Bondy M, Wiencke J, Wrensch M, Kyritsis AP. Genetics of primary brain tumors: a review. J Neurooncol 1994; 18(1): 69–81.

Preston-Martin S and Mack WJ. Neoplasms of the nervous system. InD.Schottenfeld and J.F. Fraumeni, Jr. (eds.), Cancer epidemiology and prevention (2nd ed.), p. 1231–1291, Oxford University Press, New York (1996).

Hill DA, Inskip PD, Shapiro WR,Selker RG, Fine HA, Black PM, et al. Cancer in first-degree relatives and risk of gliomain adults. Cancer Epidemiol Biomarkers Prev 2003; 12(12): 1443-8.

Goldgar DE, Easton DF, Cannon-Albright LA and Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 1994; 86(21): 1600–1608.

O’Neill BP, Blondal H, Yan P, Olafsdottir GH, Sigvaldason H, Jen-kins RB, et al. Risk of cancer among relatives of patients with glioma. Cancer EpidemiolBiomarkPrev 2002; 11(9): 921–924.

Lindelof B and Eklund G. Analysis of hereditary component of cancer by use of a familial index by site. Lancet 2001; 358(9294): 1696–1698.

Wrensch M, Lee M, Miike R, Newman B, Barger G, Davis R, et al. Familial and personal medical history of cancer and nervous ssystem conditions among adults with glioma and controls. Am J Epidemiol 1997; 145(7): 581–593.

Lunch HT, Krush AJ, Harlan WL and Sharp EA. Association of the soft tissue sarcoma, leukaemia, and brain tumors in families affected with breast cancer. Amer J Surg 1973; 39(4): 199–206.

Schlehofer B, Blettner M, Becker N, Martinsohn C, Wahrendorf J. Me¬dical risk factors and the development of brain tumors. Cancer 1992; 69(10): 2541-7.

Scheurer ME, Etzel CJ, Liu M, El-Zein R, Airewele GE, Malmer B, et al.Aggregation of cancer in first degree relatives of patients with glioma. Cancer Epidemiol Biomarkers Prev 2007; 16(11): 2491-5.

Randerson-Moor JA, Harland M, Williams S, Cuthbert-Heavens D, Sheridan E, Aveyard J, et al. A germline deletion of p14 (ARF) but not CDKN2A in a melanoma-neural system tu-mour syndrome family. Hum Mol Genet 2001; 10(1): 55–62.

Paunu N, Pukkala E, Laippala P, Sankila R, Isola J, Miettinen, et al. Cancer incidence in families with multiple glioma patients. Int J Cancer 2002; 97(6): 819–822.

Malmer B, Henriksson R, Gronberg H. Familial brain tumours-genetics or environment? A nationwide cohort study of cancer risk in spouses and first-degree relatives of brain tumour patients. Int J Cancer 2003; 106(2): 260–263.

Cicuttini FM, Hurley SF, Forbes A, Donnan GA, Salzberg M, Giles GG, et al. Association of adult glioma with medical conditions, family and reproductive history. Int J Cancer 1997; 71(2): 203-7.

Keshava C, Frye BL, Wolff MS, Mccanlies EC, Weston A. Waf-1 (p21) and p53 polymorphisms in breast cancer. Cancer EpidemiolBiomarkPrev 2002; 11(1): 127–130.

Zhou W, Liu G, Miller DP, Thurston SW, Xu LL, Wain JC, et al. Gene-environment interaction for the ERCC2 polymorphisms and cumulative cigarette smoking exposure in lung cancer. Cancer Res 2002; 62(5): 1377–1381.

Aronson SM, Aronson BE. Central nervous system in diabetes mellitus: lowered frequency of certain intracranial neoplasms. Arch Neurol 1965; 12(4): 390–8.

Atchison EA, Gridley G, Carreon JD, Leitzmann MF, Mcglynn KA. Risk of cancer in a large cohort of U.S. veterans with diabetes. Int J Cancer 2010; 128(3): 635–643.

Cahoon EK, Inskip PD, Gridley G, Brenner AV. Immune-related conditions and subsequent risk of brain cancer in a cohort of 4.5 million male US veterans. Br J Cancer 2014; 110(7): 1825–1833.

Brenner AV, Linet MS, Fine HA, Shapiro WR, Selker RG, Black PM, et al. History of allergies and autoimmune diseases and risk of brain tumors in adults. Int J Cancer 2002; 99(2): 252–259.

Schwartzbaum J, Jonsson F, Ahlbom A, Preston-Martin S, Malmer B, Lönn S, et al. Prior hospitalization for epilepsy, diabetes, and stroke and subsequent glioma and meningioma risk. Cancer Epidemiol Biomarkers Prev 2005; 14(3): 643–650.

Kitahara CM, Linet MS, Brenner AV, Wang SS, Melin BS, Wang Z, et al. Personal history of diabetes, genetic susceptibility to diabetes, and risk of brain glioma: a pooled analysis of observational studies. Cancer Epidemiol Biomarkers Prev 2014; 23(1): 47–54.

Seliger C, Ricci C, Meier C, Bodmer M, Jick SS, Bogdahn U, et al. Diabetes, use of antidiabetic drugs, and the risk of glioma. Neuro-Oncology 2016; 18(3): 340–349.

Houben MPWA, Louwman WJ, Tijssen CC, Teepen JL, Van Duijn CM, Coebergh JW. Hypertension as a risk factor for glioma? Evidence from a population-based study of comorbidity in glioma patients. Ann Oncol2004; 15(8): 1256–1260.

Houben MP, Coebergh JW, Herings RM, Casparie MK, Tijssen CC, van Duijn CM, et al. The association between antihypertensive drugs and glioma. Br J Cancer 2006; 94(5): 752–6.